23/4/2025, 12:43:03 pm

Aurobindo Pharma shares gain nearly 3%

Aurobindo Pharma gained nearly 3% in trade on Wednesday, April 23, after it said its wholly-owned subsidiary, Eugia Pharma Specialities Limited, received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dasatinib Tablets. The drug has a potential market size of $1.8 billion and is expected to launch in Q1 FY2026.